Antibody-drug conjugates: What drives their progress?

Area of Science:

• Oncology
• Pharmacology
• Immunology

Background:

• Antibody-drug conjugates (ADCs) represent a promising therapeutic strategy for targeted cancer treatment.
• ADCs deliver highly cytotoxic payloads to cancer cells, overcoming the narrow therapeutic windows of potent drugs.
• This approach aims to spare healthy tissues by concentrating drug action at the tumor site.

Purpose of the Study:

• To review currently approved Antibody-drug conjugates (ADCs).
• To discuss the mechanisms of action and medicinal chemistry of ADCs.
• To evaluate strategies for improving ADC efficacy and overcoming acquired tumor resistance.

Main Methods:

• Review of approved ADCs and their clinical applications.
• Analysis of ADC mechanisms, including payload delivery and target binding.
• Exploration of medicinal chemistry principles relevant to ADC development.
• Investigation of emerging research on immune stimulation and tumor microenvironment modulation.

Main Results:

• Approved ADCs demonstrate targeted cytotoxicity against various cancers.
• Understanding ADC mechanisms is crucial for optimizing drug design and payload selection.
• Tumor resistance can be addressed through strategies like enhancing immune responses and bystander effects.
• Recent research highlights the potential of immunogenic cell death induction.

Conclusions:

• ADCs are nearing widespread clinical adoption for cancer therapy.
• Further optimization of ADCs is possible through medicinal chemistry and understanding resistance mechanisms.
• Leveraging the immune system and tumor microenvironment offers new avenues for ADC enhancement.